These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 22963233

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
    Bohmeyer J, Stadler R, Kremer A, Nashan D, Muche M, Gellrich S, Luger T, Sterry W.
    J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
    Ballanger F, Nguyen JM, Khammari A, Dréno B.
    Dermatology; 2010 Oct; 220(4):370-5. PubMed ID: 20484880
    [Abstract] [Full Text] [Related]

  • 26. Central hypothyroidism associated with retinoid X receptor-selective ligands.
    Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M.
    N Engl J Med; 1999 Apr 08; 340(14):1075-9. PubMed ID: 10194237
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
    Singh F, Lebwohl MG.
    J Am Acad Dermatol; 2004 Oct 08; 51(4):570-3. PubMed ID: 15389192
    [Abstract] [Full Text] [Related]

  • 30. [Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders].
    Avilés Pérez MD, Luna López V, Rodríguez Nevado I, de Argila Fernández-Durán D, Díaz Pérez de Madrid J.
    An Med Interna; 2007 Dec 08; 24(12):595-8. PubMed ID: 18278999
    [Abstract] [Full Text] [Related]

  • 31. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
    Gopaluni S, Perzova R, Abbott L, Farah R, Shrimpton A, Hutchison R, Poiesz BJ.
    Am J Hematol; 2008 Sep 08; 83(9):744-6. PubMed ID: 18615708
    [Abstract] [Full Text] [Related]

  • 32. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
    Guitart J.
    Semin Oncol; 2006 Feb 08; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
    [Abstract] [Full Text] [Related]

  • 33. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
    Martin AG.
    J Drugs Dermatol; 2003 Apr 08; 2(2):155-67. PubMed ID: 12852367
    [Abstract] [Full Text] [Related]

  • 34. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
    Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD, Worldwide Bexarotene Study Group.
    J Am Acad Dermatol; 2003 Nov 08; 49(5):801-15. PubMed ID: 14576658
    [Abstract] [Full Text] [Related]

  • 35. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T, Sugaya M, Tokura Y, Ohtsuka M, Tsuboi R, Nagatani T, Tani M, Setoyama M, Matsushita S, Kawai K, Yonekura K, Yoshida T, Saida T, Iwatsuki K.
    J Dermatol; 2017 Feb 08; 44(2):135-142. PubMed ID: 27543197
    [Abstract] [Full Text] [Related]

  • 36. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.
    Quéreux G, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Dréno B.
    Expert Opin Pharmacother; 2013 Sep 08; 14(13):1711-21. PubMed ID: 23837676
    [Abstract] [Full Text] [Related]

  • 37. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J.
    Cancer Chemother Pharmacol; 2012 Feb 08; 69(2):563-71. PubMed ID: 22057855
    [Abstract] [Full Text] [Related]

  • 38. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ.
    Arch Dermatol; 2002 Mar 08; 138(3):325-32. PubMed ID: 11902983
    [Abstract] [Full Text] [Related]

  • 39. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
    French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH.
    J Am Acad Dermatol; 2001 Dec 08; 45(6):914-8. PubMed ID: 11712039
    [Abstract] [Full Text] [Related]

  • 40. [Treatment of cutaneous T-cell lymphomas with bexarotene].
    Lasa O, Izu R, Acebo E, Eguino P, Díaz-Pérez JL.
    Actas Dermosifiliogr; 2005 Dec 08; 96(10):669-73. PubMed ID: 16476317
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.